Presentation at Innovators & Investors Forum 2016

Quantum Pharma Plc

("Quantum" or the "Group")

Presentation at the Innovators & Investors Forum 2016

Quantum Pharma Plc (AIM:QP), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce that it will be exhibiting at the 2016 Innovators & Investors Forum being held today at the Business Design Centre in Islington, London. The event aims to showcase pioneering growth companies to the investor community.

Andrew Scaife, CEO of Quantum Pharma, will be a speaker at the event and his presentation will take place at 3.00 p.m. in the Babbage Room.

A copy of the presentation given by Andrew Scaife will be made available on the Group's website following the event at http://ir.quantumpharmagroup.com/content/investor/presentations.asp.

A webcast recording of the presentation will also be available to view after the event via this link: http://www.sharesmagazine.co.uk/events/event/iif2016/seminars/.

No new material or financial information will be disclosed during the course of the day.

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials

Comprising four business units:

Quantum Pharmaceutical manufactures and supplies specials and special obtains for pharmacy chains, pharmaceutical wholesalers, hospitals and independent pharmacies in the UK.

UL Medicines sources and supplies unlicensed imported medicines, batch-made and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas.

NuPharm offers outsourced manufacture for solid and liquid dose batch-made specials and niche licensed medicines, product development as well as clinical trials product manufacture.

Quantum Aseptic Services manufactures aseptically prepared, sterile intravenous products, either individually, for named patients or in batches for supply to private and NHS hospitals and homecare patients.

Niche Pharmaceuticals

Comprising three business units:

Colonis® is a product development business, which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated status.

Lamda is a full-service contract development specialist with customers across Europe. It specialises in creating added-value products with distinct advantages for patients and health care providers. It also provides full services for the entire development chain - from inception to registration to post-approval, finished product supply and regulatory support.

PERN Consumer Products, owner of the Dermacool brand - a range of menthol in aqueous creams.

Medication Adherence

Comprising two business units:

Biodose® is a medicines delivery system that accommodates liquid and solid medication, supporting medicines administration and adherence, for patients, their carers and clinicians. Biodose Connect® - a telehealth version with the ability to remotely monitor medication adherence is in live testing.

Biodose Services® assembles and delivers pre-prepared medication regimes to care homes and homecare patients, incorporating Biodose® as appropriate.

For further information, please visit www.quantumpharmagroup.com.